NasdaqGS - Nasdaq Real Time Price ? USD Sarepta Therapeutics, Inc. (SRPT) Follow Compare 127.31 +0.23 (+0.18%) At close: October 21 at 4:00 PM EDT 127.93 +0.62 (+0.49%) After hours: October 21 at 7:58 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up The three-horse race to treat a devastating form of muscular dystrophy is now down to two. And Avidity Biosciences is feeling bullish. Investor's Business Daily ? 3 days ago SRPT +0.18% FULC RNA 2 High-Flying Growth Stocks With Massive Upside Potential These innovative drugmakers have potential catalysts ahead. Motley Fool ? 4 days ago LLY SRPT +0.18% Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds? We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other promising biotech stocks. Biotechnology stocks are known for their high risk, making them some of the most volatile in the […] Insider Monkey ? 5 days ago SRPT +0.18% Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics These two could become direct competitors relatively soon. Motley Fool ? 18 days ago SRPT +0.18% WVE Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., September 30, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2024 (the "Grant Date") that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 28 individuals hired by Sarepta in September 2024. The equity awards were approved in accordance with Nasdaq Business Wire ? 21 days ago SRPT +0.18% Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts? We recently published a list of the 7 Best Revenue Growth Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other best revenue growth stocks to buy according to analysts. The Fed recently cut the funds rate by 50 […] Insider Monkey ? 21 days ago SRPT +0.18% Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress CAMBRIDGE, Mass., September 26, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 29th Annual Congress of the World Muscle Society 2024 Congress (WMS 2024), taking place Oct. 8-12, 2024, in Prague, Czechia. Business Wire ? 25 days ago SRPT +0.18% Exploring TeraWulf And Two Other High Growth Tech Stocks The market is up 1.2% over the last week and has risen 30% over the past 12 months, with earnings forecast to grow by 15% annually. In this favorable environment, identifying high-growth tech stocks like TeraWulf can be crucial for investors looking to capitalize on robust market conditions and promising future earnings potential. Simply Wall St. ? 28 days ago VNET WULF SRPT +0.18% Sarepta Therapeutics (SRPT): Soaring with Successful Therapies and Cash Flow Positivity We recently published a list of 16 Best Mid Cap Growth Stocks To Buy Now. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other best mid cap growth stocks. 50 Basis Point Reduction: Exaggeration or Hidden Benefit? Recent discussions among financial strategists emphasize the current […] Insider Monkey ? 30 days ago SRPT +0.18% Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options Investors need to pay close attention to Sarepta Therapeutics (SRPT) stock based on the movements in the options market lately. Zacks ? last month SRPT +0.18% Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors CAMBRIDGE, Mass., September 16, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly’s appointment, Sarepta’s Board will comprise nine directors, eight of whom are independent. Business Wire ? last month SRPT +0.18% Sarepta Therapeutics, Inc. (SRPT): Among Hedge Funds’ Top Biotech Stock Picks We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other biotech stocks. The ability to successfully make money through investment requires deep thinking and analysis. Even then, it’s not […] Insider Monkey ? last month SRPT +0.18% These 2 Biotech Stocks Are Set to Soar Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. Motley Fool ? last month VKTX SRPT +0.18% Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to Buy Under $1,” the […] Insider Monkey ? last month SRPT +0.18% Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report? Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks ? last month SRPT +0.18% HALO Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year CAMBRIDGE, Mass., September 05, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne muscular dystrophy and five to siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000. Business Wire ? last month SRPT +0.18% Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy On Tuesday, Dyne Therapeutics Inc. (NASDAQ:DYN) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. This assessment of the DELIVER trial evaluating DYNE-251 includes 6-month biomarker and functional data from 8 male patients enrolled in the 20 mg/kg (approximate PMO dose) cohort who were randomized to receive DYNE-251 or placebo once every four weeks and 12-month functional data from 6 p Benzinga ? last month DYN SRPT +0.18% DMD clinical studies evolve with emphasis on building designs around relevant endpoints Endpoint selection needs to be made considering the heterogeneous Duchenne muscular dystrophy population. Clinical Trials Arena ? last month PFE SRPT +0.18% Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference CAMBRIDGE, Mass., August 30, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at the New York Marriott Marquis in New York, NY. on Friday, Sept. 6, 2024, at 9:15 a.m. E.T. Business Wire ? last month SRPT +0.18% High Growth Tech Stocks To Watch In August 2024 As global markets show signs of recovery and optimism grows for a soft landing in the U.S. economy, technology stocks have been at the forefront of recent gains, with the Nasdaq Composite leading the charge. In this favorable environment for growth stocks, identifying high-potential tech companies becomes crucial for investors looking to capitalize on market momentum and innovation trends. Simply Wall St. ? last month SRPT +0.18% BEIGF BGNE Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return SRPT S&P 500 YTD +32.02% +22.73% 1-Year +14.49% +38.58% 3-Year +59.38% +29.05%
